MedTrace Logo

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

NCT02673333 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-04-06

Study results available
· View outcomes & findings →

Summary

Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.

Conditions

  • Adrenocortical Carcinoma

Interventions

DRUG

Pembrolizumab

Sponsors & Collaborators

Principal Investigators

  • Nitya Raj, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-01-11
Completion
2027-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673333 on ClinicalTrials.gov